3상모집 중

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

연구 개요

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).

스폰서: 협력: 머크(MSD)
적응증: Esophageal Squamous Cell Carcinoma
중재: Ifinatamab deruxtecan, Docetaxel, Paclitaxel, Irinotecan hydrochloride (HCl)
목표 등록: 510명
시작일: 2025-03-27
완료(예정): 2029-11-01
등록번호: NCT06644781 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.